Floatz logo

Sorafenib

Adult Glioblastoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Adult Glioblastoma cohort.

Asset / SponsorPhaseRating
Temsirolimus
University Hospital Heidelberg
Phase 2BBB
Cediranib
Lawrence Recht
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
NaviFUS Corporation
Phase 3BB
Vorinostat
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →